Experimental heterogeneity and standardisation: Stem cell products and the clinical trial process

BioSocieties

Volumn 6, Issue 4, 2011, Pages 401-419

  Webster, Andrew ^a   Haddad, Christian ^b   Waldby, Catherine ^c  

^a UNIVERSITY OF YORK   (United Kingdom)

^b UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

cells as drugs; clinical trials; ectopic life; regenerative medicine

Indexed keywords

EID: 81255179201     PISSN: 17458552     EISSN: 17458560     Source Type: Journal    
DOI: 10.1057/biosoc.2011.17     Document Type: Article

References (53)

1. Abdel-Latif, A. et al (2007) Adult bone marrow-derived cells for cardiac repair: A systematic review and meta-analysis. Archives of Internal Medicine 167(10): 989-997. (Pubitemid 46835786)
2. Abraham, J., Sheppard, J. and Reed, T. (1999) Rethinking transparency and accountability in medicines regulation in the United Kingdom. British Medical Journal 318(7175): 46-47. (Pubitemid 29188903)
3. Barriaux, M. (2007) Stem-cell hope put on hold by US regulator. The Guardian (online version), 10 January, http://www.guardian.co.uk/business/2007/ jan/10/usnews.genetics, accessed 12 November 2010.
4. Bartunek, J. et al (2006) The consensus of the task force of the European Society of Cardiology concerning the clinical investigation of the use of autologous adult stem cells for repair of the heart. European Heart Journal 27(11): 1338-1340. (Pubitemid 43998109)
5. Baylis, F. and Krahn, T. (2009) The trouble with embryos. Science Studies 22(2): 31-54.
6. Braude, P., Minger, S. and Warwick, R. (2005) Stem cell therapy: Hope or hype? British Medical Journal 330(7501): 1159-1160. (Pubitemid 40745036)
7. Callon, M., Méadel, C. and Rabeharisoa, V. (2002) The economy of qualities. Economy and Society 31(2): 194-217. (Pubitemid 34526907)
8. Caulfield, T. (2005) Legal and ethical issues associated with patient recruitment in clinical trials. Health Law Review 13(2-3): 58-61.
9. Caulfield, T. et al (2009) The stem cell research environment: A patchwork of patchworks. Stem Cell Reviews and Reports 5(2): 82-88.
10. Dawson, L. et al (2003) Safety issues in cell-based intervention trials. Fertility and Sterility 80(5): 1077-1085. (Pubitemid 37377728)
11. Deuten, J. and Rip, A. (2000) Narrative infrastructure in product creation processes. Organization 7(1): 69-93.
12. Douglas, M. (1980) Purity and Danger: An Analysis of the Concepts of Pollution and Taboo. London: Routledge and Kegan Paul.
13. Epstein, S. (2008) The rise of 'recruitmentology': Clinical research, racial knowledge, and the politics of inclusion and difference. Social Studies of Science 38(5): 801-832.
14. Eriksson, L. and Webster, A. (2008) Standardising the unknown: Practicable pluripotency as doable futures. Science as Culture 17(1): 57-69.
15. Fairchild, P.J. (2009) Transplantation tolerance in an age of induced pluripotency. Current Opinion in Organ Transplantation 14(4): 321-325.
16. Fierce Biotech. (2008) ReNeuron regulatory update. http://www. fiercebiotech.com/press-releases/ reneuron-regulatory-update-0, accessed 19 March 2008.
17. Fink, D. (2009) FDA regulation of stem-cell based products. Science 324(5935): 1662-1663.
18. Fisher, J. (2009) Medical Research for Hire: The Political Economy of Pharmaceutical Clinical Trials. Piscataway, NJ: Rutgers University Press.
19. Foley, L.A., Hicks, C. and O'Neill, P. (2011) Supply chain management in regenerative medicine manufacturing. In: D. Spath (ed.) 21st International Conference on Production Research: Innovations in Product and Production, Stuttgart, Germany (in press).
20. Freed, C.R. et al (1990) Transplantation of human fetal dopamine cells for Parkinson's disease: Results at 1 year. Archives of Neurology 47(5): 505-512. (Pubitemid 20155837)
21. Hogle, L. (2009) Pragmatic objectivity and the standardization of engineered tissues. Social Studies of Science 39(5): 717-742.
22. ISSCR. (2008) ISSCR guidelines for the clinical translation of stem cells. International Society for Stem Cell Research, http://www.isscr.org// clinical-trans/pdfs/ISSCRGLClinicalTrans.pdf, accessed 20 January 2009.
23. Jasanoff, S. (ed. 2004) States of Knowledge: The Co-production of Science and Social Order. London:
24. Routledge. Kent, J. (2008) The fetal tissue economy: From the abortion clinic to the stem cell laboratory. Social Science and Medicine 67(11): 1747-1756.
25. Latour, B. (1993) We Have Never Been Modern. Cambridge, MA: Harvard University Press.
26. Lehoux, P. (2006) The Problem of Health Technology: Policy Implications for Modern Healthy Care Systems. London: Routledge.
27. Lindvall, O. and Hyun, I. (2009) Medical innovation versus stem cell tourism. Science 324(5935): 1664-1665.
28. Lock, M. and Nguyen, V.-K. (2010) An Anthropology of Biomedicine. London: Wiley-Blackwell.
29. Martin, P., Brown, N. and Kraft, A. (2008) From bedside to bench? Communities of promise, translational research and the making of blood stem cells. Science as Culture 17(1): 29-41.
30. Mason, C. and Dunnill, P. (2008) A brief definition of regenerative medicine. Regenerative Medicine 3(1): 1-5. (Pubitemid 351541190)
31. Matsuyama, A. (2008) An overview of 'the guideline for clinical research using human stem cells'. Nippon Rinsho 66(5): 843-849.
32. Moreira, T., May, C. and Bond, J. (2009) Regulatory objectivity in action: Mild cognitive impairment and the collective production of uncertainty. Social Studies of Science 39(5): 665-690.
33. Morrison, M. and Cornips, L. (2010) Performing Futures of Regenerative Medicine. REMEDiE WP1 Project Report (May), University of York (unpublished).
34. Nowotny, H., Scott, P. and Gibbons, M. (2001) Re-thinking Science: Knowledge and the Public in an Age of Uncertainty. Cambridge: Blackwell Publishers.
35. Parson, A. (2008) Stem cell biotech: Seeking a piece of the action. Cell 132(4): 511-513. (Pubitemid 351253696)
36. Raval, A., Kamp, T. and Hogle, L. (2008) Cellular therapies for heart disease: Unveiling the ethical and public policy challenges. Journal of Molecular and Cellular Cardiology 45(4): 593-601.
37. Scrip. (2005) ReNeuron completes IPO and raises 9.5 million. Scrip 3080: 6.
38. Singh, P. and Williams, D. (2008) Cell therapies: Realizing the potential of this new dimension to medical therapeutics. Journal of Tissue Engineering and Regenerative Medicine 2(6): 307-319.
39. Stallard, N., Whitehead, J., Todd, S. and Whitehead, A. (2002) Stopping rules for phase II studies. British Journal of Clinical Pharmacology 51(6): 523-529. (Pubitemid 32862741)
40. Strauer, B. et al (2002) Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 106(15): 1913-1918. (Pubitemid 35176294)
41. Tepper, O. et al (2002) Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 106(22): 2781-2786. (Pubitemid 35396976)
42. Thomson, J.A. et al (1998) Embryonic stem cell lines derived from human blastocysts. Science 282(5391): 1145-1147. (Pubitemid 28516247)
43. TSB. (2010) Regenerative Medicine Programme: Tools and Technologies Feasibility Studies. London: Technology Strategy Board.
44. van Laake, L., Hassink, R., Doevendan, P. and Mummery, C. (2006) Heart repair and stem cells. Journal of Physiology 577(2): 467-478. (Pubitemid 44804006)
45. von Tigerstrom, B. (2009) Product regulation and the clinical translation of stem cell research. Stem Cell Reviews and Reports 5(2): 135-139.
46. Wahlberg, A. and McGoey, L. (2007) An elusive evidence base: The construction and governance of randomized controlled trials. BioSocieties 2(1): 1-10.
47. Waldby, C. and Cooper, M. (2010) From reproductive work to regenerative labour: The female body and the stem cell industries. Feminist Theory 11(1): 3-22.
48. Waldby, C. and Mitchell, R. (2006) Tissue Economies: Blood, Organs and Cell Lines in Late Capitalism. Durham, NC: Duke University Press.
49. Webster, A. and Eriksson, L. (2008) Governance-by-standards in the field of stem cells: Managing uncertainty in the world of 'basic innovation'. New Genetics and Society 27(2): 99-111. (Pubitemid 351882343)
50. Whitaker, M. (2011) Stem cell therapies: To the clinic through the clinic. Keynote presentation at the REMEDiE International Conference Bringing Regenerative Medicine to the Clinic: Trials and Tribulations in Europe and Beyond; 18-19 April, Bilbao, Spain.
51. Will, C. (2007) The alchemy of clinical trials. BioSocieties 2(1): 85-99.
52. Will, C. (2009) Identifying effectiveness in 'The Old Old': Principles and values in the age of clinical trials. Science, Technology, & Human Values 34(5): 607-628.
53. Wilson, J.M. (2009) A history lesson for stem cells. Science 324(5928): 727-728.